3 stories found
AI-native platforms are revolutionizing stem cell research, making regenerative medicine more efficient, cost-effective, and precise. This integration of artificial intelligence with biology is redefining the future of therapeutic applications.
Mark Zuckerberg has invested in Cellular Intelligence, a startup that has partnered with Novo Nordisk to acquire rights for an experimental Parkinson's treatment. The company plans to leverage artificial intelligence to accelerate the development of a cure.
Novo Nordisk has entered into a deal with Cellular Intelligence, a Zuckerberg-backed startup, to advance the development of Parkinson's cell therapy. This partnership sees Novo Nordisk handing over its Parkinson's drug development efforts to the AI-focused company.